Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

VNDA

Vanda Pharma

NASDAQ

3.760

-0.210

-5.29%

After Hours: 3.770 +0.01 +0.27% 19:38 12/08 EST

OPEN

3.960

PREV CLOSE

3.970

HIGH

3.970

LOW

3.760

VOLUME

822.08K

TURNOVER

52 WEEK HIGH

11.01

52 WEEK LOW

3.295

MARKET CAP

216.32M

P/E (TTM)

18.59

Vanda Pharma: Current report

Press release · 1d ago

Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company

Vanda pharmaceuticals acquires u.s. And canadian rights to ponvory from actelion pharmaceuticals ltd. Pon vory is approved to treat adults with relapsing forms of multiple sclerosis. Vanda paid $100 million for the rights to the drug.

Benzinga · 2d ago

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers dare bioscience (nasdaq:dare) shares rose 31.1% to $0.46 during thursday's pre-market session. Anixa biosciences shares moved upwards by 20.35%. Cerevel therapeutics hldg shares rose 14.54%. Vanda pharma stock rose 20.04%.

Benzinga · 2d ago

Vanda stock jumps on $100M license deal for MS drug from J&J unit

Vanda stock jumps on $100m license deal for ms drug from j&j unit actelion. Vanda pharmaceuticals acquires rights to relapsing multiple sclerosis drug ponvory for $100 million. Shares of vanda jumped 20% premarket.

Seeking Alpha · 2d ago

Vanda Pharmaceuticals Acquires U.S., Canadian Rights To PONVORY From Janssen

NASDAQ · 2d ago

Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug

NASDAQ · 4d ago

Vanda Pharma stock rises after FDA accepts gastroparesis drug for review

Vanda pharma stock rises after fda accepts gastroparesis drug for review. Fda accepted the new drug application for tradipitant, an experimental drug. Tradipitant is a neurokinin 1 antagonist licensed by vanda from eli lilly in 2012. Vanda shares jumped 19% premarket on tuesday.

Seeking Alpha · 4d ago

Vanda Pharmaceuticals Says FDA Accepted New Drug Application For Tradipitant For Treatment Of Gastroparesis

The fda has set september 18, 2024 as the target date for a decision. Tradipitant is the first novel drug to be approved by the fda for gastroparesis in over 40 years. The drug is being tested for the treatment of the disease in the u.s.

Benzinga · 4d ago

About VNDA

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of jet lag disorder, insomnia, delayed sleep phase disorder (DSPD), sleep disturbances in autism spectrum disorder (ASD) and pediatric Non-24 and Fanapt for the treatment of bipolar I disorder and Parkinsons disease psychosis and a long acting injectable (LAI) formulation for the treatment of schizophrenia. It offers PONVORY, to treat adults with relapsing forms of multiple sclerosis (RMS) in the United States and Canada. The Company also has a range of drugs in development, including Tradipitant (VLY-686), for the treatment of gastroparesis, motion sickness, and atopic dermatitis; VTR-297 for the treatment of hematologic malignancies, and VQW-765, for the treatment of performance anxiety and psychiatric disorders.

Webull offers Vanda Pharmaceuticals Inc. stock information, including NASDAQ: VNDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VNDA stock methods without spending real money on the virtual paper trading platform.